Healthy Volunteers
Conditions
Brief summary
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.
Detailed description
The primary PK parameter endpoints are Cmax and AUC(0-∞) for bevacizumab. The secondary PK endpoints will include all other PK parameters for bevacizumab, including tmax, t1/2, CL and AUC(0-t). The serum PK parameters of bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC\[0 ∞\] and Cmax) and AUC(0-t). The model will include a fixed effect for treatment and body weight as a covariate. All other PK parameters will not be subject to inferential statistical analysis. Estimates of geometric mean ratios together with the corresponding 90% confidence intervals (CI) will be derived for the comparisons of the PK parameters as follows: * MB02 versus EU Avastin® * MB02 versus US Avastin® * EU Avastin® versus US Avastin® PK similarity will be achieved if the 90% CIs for the biosimilar-to-reference ratios of PK endpoints (AUC\[0-∞\] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®. All AEs will be listed and summarised using descriptive methodology. All observed, or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory Activities. All safety data will be listed and summarised as appropriate. Immunogenicity data (overall anti-drug antibody \[ADA\] incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies (NAB) before the dose of MB02, EU Avastin®, or US Avastin® (Day -1) and at scheduled postdose assessments will be presented by treatment arm. All safety data and immunogenicity data summaries will be based on the safety analysis population. Select analyses may be repeated for subsets with or without ADA and de novo ADA formation as appropriate.
Interventions
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Sponsors
mAbxience Research S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Males of any race, between 18 and 55 years of age, inclusive, at Screening. 2. Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening and Check-in. 3. Total body weight between 60 and 95 kg, inclusive, at Screening and Check-in. 4. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee). 5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within the following ranges at Screening and Check in. A single repeat test will be allowed at each timepoint. * Absolute neutrophil count ≥1.5 × 109 L * Platelet count ≥100 × 109 L * Haemoglobin \>10 g/dl * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN * Alkaline phosphatase (ALP) ≤1.5 × ULN * Total bilirubin ≤ 1.5 ULN with direct bilirubin \<20% in case of total bilirubin \> ULN * Blood urea nitrogen ≤1.5 × ULN * Creatinine \<132.63 µmol/L * Serum albumin: ≥35 g/L * Total cholesterol ≤ 7.75 mmol/L * Triglycerides ≤ 3.42 mmol/L * Creatine kinase (CK) ≤3 × ULN * International normalised ratio (INR) 0.8 to 1.3 * Urine dipstick for proteinuria \<2+ 6. Systolic blood pressure ≥90 mmHg and \<140 mmHg and diastolic blood pressure ≥50 mmHg and \<90 mmHg at Screening and Check in. 7. Subjects agree to use contraception. 8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.
Exclusion criteria
1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee). 2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee). 3. Any current or recent history of active infections, including localised infections. (Within 2 months prior Screening Visit for any serious infection which requires hospitalization or intravenous anti-infective, and within 14 days prior Screening Visit for any active infection which requires oral treatment). 4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit. 5. Presence of a nonhealing wound or fracture. 6. Known history of clinically significant essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions. 7. Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study. 8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive urinary test for alcohol or drugs of abuse at Screening or Check in. 9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency. 10. History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis. 11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae. 12. Alcohol consumption of \>24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits. 13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator. 14. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study. 15. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). 16. Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee. 17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). 18. Have received a live or attenuated vaccine from 3 months prior to Screening or have the intention to receive a vaccine during the study. 19. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing. 20. Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor. 21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or positive cotinine test upon Screening or Check-in. 22. Receipt of blood products within 60 days prior to Check-in. 23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or platelets from 42 days prior to Screening. 24. Poor peripheral venous access. 25. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs. 26. Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab. 27. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study. 28. Vulnerable subjects (e.g. persons kept in detention). 29. Subjects who are study site employees or immediate family members of a study site or Mabxience employee.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax: Maximum Observed Serum Concentration | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25. |
| AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration. | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate and compare the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®. |
| t1/2: Apparent Serum Terminal Elimination Half-life | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the t1/2 of MB02, US Avastin® and EU Avastin® |
| CL: Total Body Drug Clearance After IV Administration | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate the CL of MB02, US Avastin® and EU Avastin® |
| Number of Participants With Treatment-emergent Adverse Events (Safety) | Day 1 - Day 100 | Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
| Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | Day -1, Day 14, Day 28, Day 56, and Day 78 | Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here. Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row. |
| Tmax: Time of Maximum Observed Serum Concentration | Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100. | To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® . |
Countries
Germany
Participant flow
Pre-assignment details
One subject in the US Avastin arm withdrew before receiving any study treatment.
Participants by arm
| Arm | Count |
|---|---|
| MB02 (Bevacizumab Biosimilar) Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
MB02 (Bevacizumab Biosimilar): Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion | 38 |
| EU Approved Avastin® Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
EU approved Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion | 38 |
| US Licenced Avastin® Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
US licenced Avastin®: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion | 38 |
| Total | 114 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | MB02 (Bevacizumab Biosimilar) | EU Approved Avastin® | US Licenced Avastin® | Total |
|---|---|---|---|---|
| Age, Continuous | 39.4 years STANDARD_DEVIATION 10.18 | 41.6 years STANDARD_DEVIATION 11.1 | 38.3 years STANDARD_DEVIATION 9.64 | 39.8 years STANDARD_DEVIATION 10.33 |
| Body mass index (BMI) | 24.48 kg/m^2 STANDARD_DEVIATION 2.723 | 24.59 kg/m^2 STANDARD_DEVIATION 2.322 | 24.80 kg/m^2 STANDARD_DEVIATION 2.712 | 24.62 kg/m^2 STANDARD_DEVIATION 2.573 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 38 Participants | 37 Participants | 37 Participants | 112 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 36 Participants | 35 Participants | 37 Participants | 108 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 38 Participants | 38 Participants | 38 Participants | 114 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 38 | 0 / 38 | 0 / 38 |
| other Total, other adverse events | 30 / 38 | 25 / 38 | 32 / 38 |
| serious Total, serious adverse events | 0 / 38 | 0 / 38 | 0 / 38 |
Outcome results
Primary
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 30700000 ng*h/mL | Geometric Coefficient of Variation 16.2 |
| EU Approved Avastin® | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 28800000 ng*h/mL | Geometric Coefficient of Variation 16.4 |
| US Licenced Avastin® | AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity | 30700000 ng*h/mL | Geometric Coefficient of Variation 12.9 |
90% CI: [1, 1.14]
90% CI: [0.944, 1.05]
90% CI: [0.884, 0.988]
Primary
Cmax: Maximum Observed Serum Concentration
To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Cmax: Maximum Observed Serum Concentration | 86100 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 24.8 |
| EU Approved Avastin® | Cmax: Maximum Observed Serum Concentration | 81100 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 20 |
| US Licenced Avastin® | Cmax: Maximum Observed Serum Concentration | 87500 (ng/mL)/(mg/mL) | Geometric Coefficient of Variation 24.9 |
90% CI: [0.976, 1.16]
Comparison: For the comparison, MB02 represents the numerator and US Avastin represents the denominator.90% CI: [0.897, 1.08]
90% CI: [0.851, 1.01]
Secondary
AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.
To evaluate and compare the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration. | 29900000 ng*h/mL | Geometric Coefficient of Variation 15.6 |
| EU Approved Avastin® | AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration. | 27900000 ng*h/mL | Geometric Coefficient of Variation 16 |
| US Licenced Avastin® | AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration. | 29900000 ng*h/mL | Geometric Coefficient of Variation 12.5 |
Secondary
CL: Total Body Drug Clearance After IV Administration
To evaluate the CL of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | CL: Total Body Drug Clearance After IV Administration | 0.00770 l/hour | Geometric Coefficient of Variation 18.1 |
| EU Approved Avastin® | CL: Total Body Drug Clearance After IV Administration | 0.00823 l/hour | Geometric Coefficient of Variation 18.5 |
| US Licenced Avastin® | CL: Total Body Drug Clearance After IV Administration | 0.00766 l/hour | Geometric Coefficient of Variation 16.2 |
Secondary
Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)
Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here. Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.
Time frame: Day -1, Day 14, Day 28, Day 56, and Day 78
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | ADA positive | 12 participants |
| MB02 (Bevacizumab Biosimilar) | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | NAb positive | 1 participants |
| EU Approved Avastin® | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | ADA positive | 14 participants |
| EU Approved Avastin® | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | NAb positive | 0 participants |
| US Licenced Avastin® | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | ADA positive | 9 participants |
| US Licenced Avastin® | Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies) | NAb positive | 2 participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (Safety)
Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time frame: Day 1 - Day 100
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Not related TEAEs | 16 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of severe severity | 0 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Possibly related TEAEs | 10 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Unlikely-related TEAEs | 4 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with TEAEs | 30 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of moderate severity | 10 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects discontinued due to TEAEs | 0 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with SAEs | 0 participants |
| MB02 (Bevacizumab Biosimilar) | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of mild severity | 20 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Unlikely-related TEAEs | 2 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with TEAEs | 25 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with SAEs | 0 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects discontinued due to TEAEs | 0 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Not related TEAEs | 12 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Possibly related TEAEs | 11 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of mild severity | 10 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of moderate severity | 14 participants |
| EU Approved Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of severe severity | 1 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects discontinued due to TEAEs | 0 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with TEAEs | 32 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of mild severity | 23 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Subjects with SAEs | 0 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of severe severity | 0 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Unlikely-related TEAEs | 4 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Not related TEAEs | 16 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | TEAEs of moderate severity | 9 participants |
| US Licenced Avastin® | Number of Participants With Treatment-emergent Adverse Events (Safety) | Possibly related TEAEs | 12 participants |
Secondary
t1/2: Apparent Serum Terminal Elimination Half-life
To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (GEOMETRIC_LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| MB02 (Bevacizumab Biosimilar) | t1/2: Apparent Serum Terminal Elimination Half-life | 443 hours | Geometric Coefficient of Variation 16.9 |
| EU Approved Avastin® | t1/2: Apparent Serum Terminal Elimination Half-life | 444 hours | Geometric Coefficient of Variation 14.5 |
| US Licenced Avastin® | t1/2: Apparent Serum Terminal Elimination Half-life | 458 hours | Geometric Coefficient of Variation 16.1 |
Secondary
Tmax: Time of Maximum Observed Serum Concentration
To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .
Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MB02 (Bevacizumab Biosimilar) | Tmax: Time of Maximum Observed Serum Concentration | 4.0 hours |
| EU Approved Avastin® | Tmax: Time of Maximum Observed Serum Concentration | 4.0 hours |
| US Licenced Avastin® | Tmax: Time of Maximum Observed Serum Concentration | 4.0 hours |